Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Vivos Therapeutics (VVOS) EBITDA (2020 - 2025)

Vivos Therapeutics has reported EBITDA over the past 6 years, most recently at -$6.6 million for Q4 2025.

  • Quarterly EBITDA fell 143.24% to -$6.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$19.2 million through Dec 2025, down 78.23% year-over-year, with the annual reading at -$19.2 million for FY2025, 79.87% down from the prior year.
  • EBITDA was -$6.6 million for Q4 2025 at Vivos Therapeutics, down from -$4.3 million in the prior quarter.
  • Over five years, EBITDA peaked at $8.8 million in Q4 2021 and troughed at -$6.8 million in Q2 2022.
  • The 5-year median for EBITDA is -$4.2 million (2021), against an average of -$3.7 million.
  • The largest YoY upside for EBITDA was 240.69% in 2021 against a maximum downside of 226.46% in 2021.
  • A 5-year view of EBITDA shows it stood at $8.8 million in 2021, then plummeted by 165.41% to -$5.8 million in 2022, then skyrocketed by 31.75% to -$3.9 million in 2023, then soared by 31.2% to -$2.7 million in 2024, then crashed by 143.24% to -$6.6 million in 2025.
  • Per Business Quant, the three most recent readings for VVOS's EBITDA are -$6.6 million (Q4 2025), -$4.3 million (Q3 2025), and -$4.6 million (Q2 2025).